Summary & Key Points

• BBOT filed its 2025 Annual Report (10-K) as a public company on the Nasdaq Global Market under the symbol “BBOT”.
• No products approved or commercialized yet; the company is pre-revenue and has not completed any clinical trials.
• BBOT operates as an “emerging growth company” and “smaller reporting company”, impacting its regulatory and reporting requirements.
• 80,032,823 shares outstanding as of March 2, 2026.
• Specified portions of the 2026 Proxy Statement are incorporated by reference into Part III of the 10-K.

Potentially Price-Sensitive Information for Shareholders

• BBOT has no products approved for sale and has never generated revenue. Its entire valuation is based on future potential and pipeline development.
• BBOT has not completed any clinical trials as of the 2025 fiscal year end. Investors should be aware that product candidates are still in early stages.
• The company has identified material weaknesses in internal controls over financial reporting in the past, which may impact confidence in financial reporting and governance.
• BBOT is subject to stringent privacy and information security regulations, which may lead to increased compliance costs or legal exposure.
• As an emerging growth company, BBOT has reduced regulatory burdens, but may also face increased volatility and operational risks.
• Market Risk: There may not be an active trading market for BBOT shares, and liquidity could be limited, affecting the ability of investors to buy or sell at desired prices.
• The company’s success is highly dependent on attracting and retaining key scientific and management personnel.
• Future sales by the company or large shareholders, or the perception of such sales, could pressure the share price downward.
• BBOT’s future depends on advancing its product candidates, obtaining regulatory approvals, and successful commercialization.
• Unfavorable macroeconomic conditions, inflation, interest rate increases, geopolitical instability, and regulatory uncertainty are highlighted as significant risks.

Forward-Looking Statements & Risk Factors

The annual report contains extensive forward-looking statements regarding BBOT’s strategy, future operations, operating expenses, financial position, and product pipeline prospects. The company emphasizes that these statements come with substantial risks, uncertainties, and assumptions.

Corporate & Regulatory Information

• Legal Entity: BridgeBio Oncology Therapeutics, Inc.
• Location: Washington, D.C. 20549 (SEC filing jurisdiction)
• Trading Exchange: Nasdaq Global Market
• Security Registered: Common Stock, par value \$0.0001 per share (Ticker: BBOT)
• Reporting Status:
  • Not a well-known seasoned issuer
  • Is a smaller reporting company
  • Is an emerging growth company
  • Not a shell company
• Regulatory Compliance:
  • All required Exchange Act filings completed in the last 12 months
  • All required Interactive Data Files submitted as per Regulation S-T
  • No financial statement restatements or error corrections reported for this filing
  • No auditor attestation report on internal control over financial reporting (as permitted for emerging growth companies)

What Should Investors Watch?

• BBOT’s future value is entirely dependent on the progress of its drug development pipeline, which is at a preclinical or very early clinical stage.
• Milestones that could move the share price:
  • Announcement of successful clinical trial initiation or completion
  • Regulatory submissions or approvals
  • Significant partnerships, licensing deals, or capital raises
  • Key executive hires or departures
  • Resolution of any material weaknesses in internal control
• Investors should monitor filings for updates on the risk and progress of the pipeline, as well as market conditions affecting emerging growth biotech companies.